Artivion Inc (AORT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Artivion Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 26.80 $ — 24% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 12.0% failed
- More than 10% revenue growth is expected for the coming year 11.0% passed
- Share count grows by less than 3% a year 5.6% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 13.4% failed
- Gross margin at 40% or higher and without meaningful erosion 61.3% failed
- Goodwill from acquisitions does not grow faster than revenue 28.7% passed
- Net debt below twice EBITDA 3.6 x EBITDA failed
- Operating cash flow covers the profits of the last three years 113 m passed
- Return on capital at 15% or higher, or up versus two years ago 3.4% passed
- Insiders hold at least 10% or are net buyers 4.5% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 56.7% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 6
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.44 | 0.37 – 0.52 | 486 | -29.9% | 6 |
| 12/31/2027 | 0.72 | 0.52 – 0.85 | 540 | 63.0% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.13 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.39 | – | 97 | 3.90 | -16.90 | 10 | 9 |
| 2025: Q1 | -0.01 | -107.60 | 99 | 1.60 | -0.50 | -17 | -21 |
| 2025: Q2 | 0.03 | – | 113 | 15.30 | 1.20 | 15 | 12 |
| 2025: Q3 | 0.13 | – | 113 | 18.40 | 5.70 | 21 | 16 |
| 2025: Q4 | 0.05 | – | 116 | 19.20 | 2.10 | 20 | -8 |
| 2026: Q1 | 0.03 | – | 116 | 17.50 | 1.20 | 1 | -7 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 180 | 22 | 11 | 0.33 | 20 | 209 | 316 |
| 2017 | 190 | 8 | 4 | 0.11 | 11 | 279 | 592 |
| 2018 | 263 | 9 | -4 | -0.10 | 10 | 275 | 571 |
| 2019 | 276 | 17 | 2 | 0.05 | 16 | 286 | 606 |
| 2020 | 253 | 2 | -17 | -0.44 | 12 | 329 | 789 |
| 2021 | 299 | 8 | -15 | -0.38 | -3 | 301 | 793 |
| 2022 | 314 | 6 | -19 | -0.48 | -5 | 284 | 763 |
| 2023 | 354 | 6 | -31 | -0.75 | 19 | 282 | 792 |
| 2024 | 389 | 39 | -13 | -0.32 | 22 | 276 | 789 |
| 2025 | 441 | 27 | 10 | 0.21 | 38 | 448 | 885 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Artivion, Inc. fertigt, verarbeitet und vertreibt weltweit Medizinprodukte und implantierbare menschliche Gewebe.
| Employees | 1,800 |
|---|---|
| Headquarters | Kennesaw, GA |
| Address | 1655 Roberts Boulevard NW, 30144 Kennesaw, United States |
| Phone | 770 419 3355 |
| Website | artivion.com |
| IPO Date | 12. Feb 1993 |
| ISIN | US2289031005 |
| Stock Split | 3:2 on 12/28/2000 |
Management
| Name | Title | Birth Year |
|---|---|---|
| James Patrick Mackin | Chairman, President & CEO | 1967 |
| Lance A. Berry CPA | EVP, COO, CFO & Treasurer | 1972 |
| Jean F. Holloway Esq. | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 1957 |
| John E. Davis | Senior VP & Chief Commercial Officer | 1965 |
| Amy D. Horton CPA | VP & Chief Accounting Officer | 1970 |
| Matthew A. Getz | VP of Human Resources & Chief Human Resources Officer | 1969 |
| Jason D. Asper | Senior VP and Chief Strategy & Digital Officer | 1976 |
| Andrew M. Green | Senior Vice President of Regulatory & Quality | 1969 |
| Simona Zannetti M.D. | Senior Vice President of Clinical Research & Chief Medical Officer | – |
| Robert C. Thomson Ph.D. | Vice President of Research & Development | 1971 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.